Home Healthcare IT Global Capecitabine Market Size, Top Share to 2031

Capecitabine Market

Capecitabine Market Size, Share & Trends Analysis Report By Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), By Drug Formulation (Tablets, Capsules) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI206DR
Study Period 2020-2032 CAGR %
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD XX Billion
Forecast Year 2032 Forecast Year Market Size USD XX Billion
Largest Market America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

Capecitabine is a chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Cancer is the second leading cause of death worldwide–around 9.6 million deaths every year are caused by cancer, WHO. In addition, more than 70% of deaths occur in low and middle-income countries. Thereon, with the increasing prevalence of cancer incidences worldwide, the overall demand for chemotherapeutic agents has increased significantly. Capecitabine has huge potential to meet the increasing need for new agents, which can more aggressively treat breast cancer in the earlier stages.

Global capecitabine market accounted for around USD 1,652 million in 2017 and is expected to grow at a healthy CAGR during the forecast period, 2023–2031.

Market Dynamics

  • Capecitabine Manufacturers
  • Raw Material Suppliers
  • Capecitabine Reselling Companies
  • Potential Investors
  • Research and Development Institutes
  • Traders, Distributors, and Suppliers of Capecitabine

Regional Analysis

Geographically, the global capecitabine market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA).

The Americas is projected to dominate the global capecitabine market due to increasing prevalence of cancer in the region. Around 1,735,350 new cases of cancer were reported in 2018, National Cancer Institute. In line with this, many players are engaged in developing better treatment options. For instance, Puma Biotechnology has received positive results from the company’s lead drug Neratinib used in breast cancer. The treatment involves combination therapy with capecitabine.

Europe is the second largest market globally. This can be attributed to rising incidences of cancers, which is the second leading cause of death and morbidity in Europe. Around 3.7 million new cases occur each year in Europe, WHO. Novel therapies are the need of the hour in the region. Around USD 1.5 billion has been invested by the European government on cancer research, European Commission.

Asia Pacific is expected to witness significant growth. The region houses huge tobacco consuming population, killing more than 2.3 million every year. However, lack of awareness in the region is leading to delay in the detection of cancer. In 2018, most of the new cancer cases were diagnosed from Eastern Asia around 5.6 million, according to Cancer Organization. To educate people about symptoms and diagnosis of cancer, governments are conducting many programs and screening drives.

MEA is expected to witness steady growth as a result of growing burden of cancer on the Middle East & Africa region due to poor healthcare facilities.

Report Scope

Report Metric Details
Segmentations
By Application
  1. Colon Cancer
  2. Rectal Cancer
  3. Breast Cancer
  4. Gastric Cancer
  5. Others
By Drug Formulation
  1. Tablets
  2. Capsules
Company Profiles Fresenius SE & Co. KGaA (Germany) Genentech, Inc. (U.S.) Dr Reddy Laboratories Ltd. (India) Cipla Inc. (India) Accord Healthcare Ltd. (U.K.) F. Hoffmann-La Roche Ltd. (Switzerland) Teva Pharma B.V., Sandoz Inc. (U.S.) Zentiva N.V. (Netherlands) Ranbaxy Laboratories Ltd. (India)
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Global capecitabine market is segmented

By application and drug formulation.

By application, the market is segmented into colon cancer, rectal cancer, breast cancer, gastric cancer, and others.

By drug formulation, capecitabine market is segmented into tablets and capsules. Tablets segment is expected to dominate due to high production by manufacturers.

Market Size By Application

Top Key Players

Fresenius SE & Co. KGaA (Germany) Genentech, Inc. (U.S.) Dr Reddy Laboratories Ltd. (India) Cipla Inc. (India) Accord Healthcare Ltd. (U.K.) F. Hoffmann-La Roche Ltd. (Switzerland) Teva Pharma B.V., Sandoz Inc. (U.S.) Zentiva N.V. (Netherlands) Ranbaxy Laboratories Ltd. (India) Others

Frequently Asked Questions (FAQs)

Which region has the highest growth rate in the capecitabine market?
Asia Pacific region has the highest growth rate in the capecitabine market.
Key verticals adopting capecitabine include: - Fresenius SE & Co. KGaA, Genentech, Inc, Dr Reddy Laboratories Ltd, Cipla Inc, Accord Healthcare Ltd, F. Hoffmann-La Roche Ltd, Teva Pharma B.V., Sandoz Inc, Zentiva N.V, Ranbaxy Laboratories Ltd.
Tablets segment is the leading segment for the market during forecast period.


We are featured on :

This website uses cookies to ensure you get the best experience on our website. Privacy Policy